BetterRX
Why This Evaluation Is Happening Now
Most hospice leaders don't set out to research PBM alternatives out of curiosity. Something specific triggers the search: a budget review that turns up an unexplained cost spread, a merger or acquisition that suddenly needs to standardize medication management across new locations, or a nursing team that's grown vocal about how much time it loses to phone calls and faxes. By the time the evaluation starts, the operational cost of staying put is already visible.
That's the right starting point for this decision. Before comparing any specific platform or pharmacy partner, it helps to name what's actually not working: Is it cost visibility? Delivery speed? Formulary control? Standardization across sites? A clear answer to that question does more to guide the evaluation than any feature checklist.
What Makes an Operating Model Different from a Vendor Swap
It's easy to treat this search as "which company should we switch to," but the more useful frame is "which operating model actually fits a per-diem hospice benefit." The traditional PBM model was built to manage pharmacy benefits across large populations of commercially insured members, where the priorities are rebate negotiation and network scale. Hospice runs on a different structure entirely: a fixed per-diem payment where the hospice organization itself bears the medication cost, and where a patient's needs can escalate within hours, not weeks.
A Practical Evaluation Framework
Rather than starting with a feature-by-feature comparison, most CEOs and COOs get further by starting with outcomes and working backward. Five outcomes tend to matter most in this evaluation: Patient Care, Predictable PPD, Nurse Satisfaction, Time Savings, and Organizational Growth. A useful evaluation question for each: can the current model, or the alternative under consideration, actually move this number, or does it just describe it after the fact?
How BetterRX Approaches the Decision
BetterRX doesn't ask hospice leaders to take a position on whether a given vendor is or isn't technically a PBM. The more useful question is whether the operating model was actually built for hospice's per-diem structure and its clinically urgent, unpredictable medication needs, or adapted from a model built for something else. BetterRX combines Intelligent Medication Management, a Custom Tailored Pharmacy Alliance, and Top-Rated Client Support, purpose-built exclusively for hospice since 2007, to deliver The Better Way to Manage Hospice Medications.
Transparent, pass-through pricing means BetterRX doesn't profit from medication or delivery markups, keeping incentives aligned with the hospice: better care, lower unnecessary costs, and medications that reach patients as quickly as possible. In BetterRX's 2026 Voice of the Customer survey, 99% of clients rate BetterRX as a highly trusted partner, and BetterRX has earned an “A” Voice of the Customer rating six years in a row.
I cannot say enough good things about everyone at BetterRX. Customer and clinical support is outstanding."
— VOC respondent
That kind of sustained trust is a meaningful data point in its own right during an evaluation: a model that keeps earning strong ratings year after year is a model that's holding up under real operating conditions, not just performing well in a first demo. Buyers evaluating any alternative, BetterRX included, should weigh a multi-year trend over a single point-in-time score, since a model that's genuinely built for hospice tends to show it through consistency rather than a one-time high mark.
Common Evaluation Mistakes to Avoid
A few patterns tend to derail this evaluation before it produces a good decision. The first is comparing only headline pricing across proposals, without asking each vendor to show its actual cost breakdown, which makes a spread-based model look identical to a transparent one on paper. The second is evaluating a single flagship location's experience and assuming it will hold up the same way everywhere else the hospice operates, when in practice a model's real weaknesses often only show up at a second or third site. The third is treating the decision as purely a procurement exercise owned by finance, without input from the clinical leaders and nurses who will actually use the platform every day.
A fourth, subtler mistake is assuming any hospice PBM alternative automatically fixes the underlying problem. Switching models without also standardizing training, onboarding, and formulary management across every location can leave the same operational variation in place under a new name. The decision that actually moves the needle combines the right operating model with a disciplined rollout across the whole organization.
Making the Decision Stick
A hospice PBM alternative only delivers value if the switch actually gets adopted across every team and location, not just piloted at headquarters. Standardized onboarding, Client Success Expertise, and a platform simple enough that nurses genuinely prefer it over the old process are what separate a strategic decision from a paper change. Connecting the choice back to financial stewardship and organizational growth, rather than treating it as a one-time procurement exercise, is what keeps the decision paying off well past the first year.
Compare how The Better Way to Manage Hospice Medications stacks up against your current model's cost visibility, incentive alignment, and support.
